Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

70%

16 trials in Phase 3/4

Results Transparency

43%

9 of 21 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 3
11(50.0%)
Phase 4
5(22.7%)
Phase 2
3(13.6%)
Phase 1
2(9.1%)
N/A
1(4.5%)
22Total
Phase 3(11)
Phase 4(5)
Phase 2(3)
Phase 1(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT01086904Phase 2Completed

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

Role: collaborator

NCT01024400Phase 2Completed

Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women

Role: collaborator

NCT02868970Phase 4Completed

Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction

Role: collaborator

NCT00386542Phase 1Completed

Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children

Role: collaborator

NCT02759354Phase 3Completed

Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)

Role: lead

NCT02640118Not ApplicableCompleted

The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects

Role: collaborator

NCT01341639Phase 3Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Role: lead

NCT00223080Phase 3Completed

HIV Vaccine Trial in Thai Adults

Role: collaborator

NCT01480258Phase 3Completed

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Role: lead

NCT01553279Phase 3Completed

Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)

Role: lead

NCT01839188Phase 3Completed

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Role: lead

NCT01337167Phase 3Completed

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

Role: collaborator

NCT01340937Phase 3Completed

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Role: collaborator

NCT01525004Phase 1Completed

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

Role: collaborator

NCT01147510Phase 4Completed

Asthma Control in Elderly Patients With Montelukast

Role: collaborator

NCT00740935Phase 4Completed

Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.

Role: collaborator

NCT00670839Phase 3Completed

Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)

Role: collaborator

NCT00480792Phase 3Completed

Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients

Role: collaborator

NCT01897129Unknown

Human Papillomavirus and Pregnancy

Role: collaborator

NCT00125502Phase 2Completed

Recombinant CMV gB Vaccine in Postpartum Women

Role: collaborator